Latest News and Press Releases

Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J

Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates.

NDAs for Toripalimab Injection (Subcutaneous) Across 12 Indications accepted by the NMPA

Jointly evaluate the synergistic therapeutic potential of JS207 (PD-1/VEGF BsAb) and ATG-037 (oral small-molecule CD73 inhibitor)

Promising long-term survival results from toripalimab's JUPITER-02 and JUPITER-06 presented at the ESMO ASIA

BLA of Roconkibart (IL-17A) for the treatment of moderate to severe plaque psoriasis has been accepted by the NMPA

The phase 3 study of toripalimab's subcutaneous injection (JS001sc) has met primary endpoints

FDA has approved Junshi Biosciences' IND for a Phase 2/3 clinical study of JS207 (PD-1/VEGF), for the neoadjuvant treatment of NSCLC

JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study

Junshi Biosciences announced its 2025 interim financial results and provided corporate updates.